CD271 Targeted Near-Infrared Photoimmunotherapy for Local Depletion of Cancer Stem Cells
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c01157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Ryosuke Takahashi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Institute of Science Tokyo, Tokyo 113-8519, Japan. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Immunotherapy, Receptors, Nerve Growth Factor, Head and Neck Neoplasms. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Intramural Research Program, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Cancer stem cells have the ability to self-renew and show resistance to conventional drug therapy and radiation therapy, potentially resulting in cancer recurrence and metastasis. Since inadequate treatment of cancer stem cells can cause local recurrence and metastasis, an important goal of cancer therapy is to target these cancer stem cells. Near-infrared photoimmunotherapy (NIR-PIT) is one of the cell-selective cancer treatments. Cancer stem cell can be locally depleted by NIR-PIT using appropriate antibody-photoabsorber (IR700) conjugates (APCs). In this study, the efficacy of NIR-PIT against CD271, which has been reported as a marker of cancer stem cells in various cancers, including head and neck cancers, was confirmed using two different human head and neck cancer cell lines, HPCM2 and HSC-3. We demonstrated the efficacy of NIR-PIT against CD271 in both in vitro and in vivo experiments. The efficacy of CD271-targeted NIR-PIT was comparable to that of EGFR-targeted NIR-PIT in mouse models, even though the cell-surface expression of CD271 was lower than that of EGFR. This is the first study to demonstrate the efficacy of CD271-targeted NIR-PIT, which we believe will have a significant impact on the future development of cancer stem cell-targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Institute of Science Tokyo, Tokyo 113-8519, Japan.
- Department of Dental Radiology and Radiation Oncology, Institute of Science Tokyo, Tokyo 113-8519, Japan.
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
- Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiote, Natori, Miyagi 981-1293, Japan.
ORCID-Profile: Ryosuke Takahashi, Hisataka Kobayashi, Ryuhei Okada
Förderung
- Intramural Research Program
- Japan Society for the Promotion of Science
Zitieren
APA
Takahashi, R., Kaida, A., Nojima, H., Okuyama, S., Mochizuki, M., Morita, S., Tamai, K., Miura, M., Kobayashi, H., Asakage, T., & Okada, R. (2025). CD271 Targeted Near-Infrared Photoimmunotherapy for Local Depletion of Cancer Stem Cells. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01157
Vancouver
Takahashi R, Kaida A, Nojima H, Okuyama S, Mochizuki M, Morita S, et al. CD271 Targeted Near-Infrared Photoimmunotherapy for Local Depletion of Cancer Stem Cells. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01157
BibTeX
@article{Takahashi2025,
author = {Takahashi, Ryosuke and Kaida, Atsushi and Nojima, Hitomi and Okuyama, Shuhei and Mochizuki, Mai and Morita, Shinkichi and Tamai, Keiichi and Miura, Masahiko and Kobayashi, Hisataka and Asakage, Takahiro and Okada, Ryuhei},
title = {CD271 Targeted Near-Infrared Photoimmunotherapy for Local Depletion of Cancer Stem Cells},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c01157}
}
EUVIMED